-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TTnId70v004iCQ50XocXtLfo6jhKN1b9whyj6p/TpbvA+4NEBPnp1MfyrvlDhNr4
 B0KQrIFuWLYddrVgTuzVdQ==

<SEC-DOCUMENT>0001144204-07-015298.txt : 20070329
<SEC-HEADER>0001144204-07-015298.hdr.sgml : 20070329
<ACCEPTANCE-DATETIME>20070329170124
ACCESSION NUMBER:		0001144204-07-015298
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070329
FILED AS OF DATE:		20070329
DATE AS OF CHANGE:		20070329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		07728344

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v069831_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      March
      29, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Ltd.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
        <hr style="COLOR: black" align="center" noshade size="2" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant's name into English)</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
      York, New York 10022</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="2" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="20%">&#160;</td>
            <td width="20%">&#160;</td>
            <td width="20%"><font size="2">Form 20-F <font face="Wingdings">x</font></font></td>
            <td width="20%"><font size="2">Form 40-F <font face="Wingdings">o</font></font></td>
            <td width="20%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="20%">&#160;</td>
            <td width="20%">&#160;</td>
            <td width="20%"><font size="2">Yes <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></td>
            <td width="20%"><font size="2">No <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></td>
            <td width="20%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><IMG SRC="xtlbio.jpg"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Inc. Announces the Completion of Phase I Study with
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>XTL-6865
      in Patients with Chronic Hepatitis C</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
      York, New York, March 29, 2007</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today
      the
      completion of the Phase I study with XTL-6865. The primary goal of this Phase
      I
      study was to evaluate safety and pharmacokinetic properties of XTL-6865 in
      patients with chronic hepatitis C. XTL-6865, which targets the E2 envelope
      protein of the hepatitis C virus, is comprised of two fully-human monoclonal
      antibodies and is administered intravenously. The study enrolled 32 patients
      into 8 cohorts, each comprised of 3 treated patients and 1 placebo patient.
      Of
      the 8 cohorts in the study, the first 7 were single administration cohorts
      with
      doses ranging from 5mg to 2400mg. The 8</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      cohort
      received 1200mg for 5 consecutive days. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      this
      study, XTL-6865 was shown to be safe at high doses (up to 1200mg for 5
      consecutive daily doses and a single dose of 2400mg). The study also enabled
      the
      Company to establish the pharmacokinetic properties of XTL-6865 in patients
      with
      chronic hepatitis C</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      all
      single doses, the t</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sub>max</sub></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      was
      reached immediately at the end of the XTL-6865 infusion. For the highest single
      dose, 2400mg, the C</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sub>max</sub></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      was
      between 500 and 1000 </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">m</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g/ml
      and
      the t</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sub>&#189;</sub></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      was
      approximately 5 days. For the lower single doses, the t</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sub>&#189;</sub></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      was 2-3
      days.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      study provided evidence of binding of the antibody to circulating virus and
      the
      formation of immune complexes (antibody-virus), believed to be important for
      virus neutralization in the serum. No statistically significant changes in
      HCV-RNA were observed. Given the short duration of administration of XTL-6865,
      and the fact the patients in this study had a high rate of viral replication
      at
      baseline, no significant change in viral load was to be expected. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      results of this Phase I trial potentially pave the way for trials that would
      evaluate XTL-6865 in patients with hepatitis C undergoing liver transplantation
      - a potential target patient population for this drug - or in chronic hepatitis
      C patients with low viral load. XTL intends to seek a collaborative partnership
      for the future development of this compound. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, CEO of XTL Biopharmaceuticals, commented, &#8220;This trial enabled us to
      determine the pharmacokinetic properties of XTL-6865, and to demonstrate that
      it
      could be safely administered to patients at high doses. This study also clearly
      demonstrated that the antibody binds to the circulating virus in the serum.
      We
      believe that XTL-6865 could potentially play a role in certain clinical
      settings, such as preventing re-infection of hepatitis C following liver
      transplantation or in chronic hepatitis C patients who have low viral loads
      following treatment with other anti-hepatitis C drugs. We believe this is now
      an
      appropriate time to seek to out-license the compound.&#8221; Mr. Bentsur continued,
&#8220;We intend to focus our resources on commencing our clinical program for
      Bicifadine, for the treatment of diabetic neuropathic pain, and on completing
      our Phase I study for XTL-2125, our small-molecule compound for the treatment
      of
      chronic hepatitis C.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the acquisition, development and
      commercialization of therapeutics for the treatment of neuropathic pain and
      hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
      reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL
      is
      developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
      hepatitis C virus polymerase. XTL-2125 is currently in a Phase I clinical trial
      in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
      combination of two monoclonal antibodies against the hepatitis C virus. XTL&#8217;s
      hepatitis C pipeline also includes several families of pre-clinical hepatitis
      C
      small molecule inhibitors. &#160;XTL also has an active in-licensing and
      acquisition program designed to identify and acquire additional drug candidates.
      XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
      (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(212)-531-5960</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future performance, clinical and business prospects for our
      clinical compound for neuropathic pain, Bicifadine, and for our clinical
      compounds for hepatitis C, XTL-2125 and XTL-6865, growth and operating
      strategies and similar matters, may be forward-looking statements that involve
      a
      number of risks and uncertainties. For those statements, we claim the protection
      of the safe harbor for forward-looking statements contained in the Private
      Securities Litigation Reform Act of 1995. Among the factors that could cause
      our
      actual results to differ materially are the following: our ability to start
      a
      clinical trial with Bicifadine in 2007; our ability to meet the forecast
      reporting deadlines for the XTL-2125 clinical trial that we mentioned above;
      our
      ability to successfully complete cost-effective clinical trials for the drug
      candidates in our pipeline which would affect our ability to continue to fund
      our operations with our available cash reserves, our ability to meet anticipated
      development timelines for the drug candidates in our pipeline due to
      recruitment, clinical trial results, manufacturing capabilities or other
      factors; and other risk factors identified from time to time in our reports
      filed with the Securities and Exchange Commission and the London Stock Exchange,
      including our annual report on Form 20-F filed with the Securities and Exchange
      Commission on March 23, 2007. Any forward-looking statements set forth in this
      press release speak only as of the date of this press release. We do not intend
      to update any of these forward-looking statements to reflect events or
      circumstances that occur after the date hereof. This press release and prior
      releases are available at http://www.xtlbio.com. The information in our website
      is not incorporated by reference into this press release and is included as
      an
      inactive textual reference only. </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;March
              29, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Chief
              Executive Officer </font></td>
          </tr>

      </table><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      report on Form 6-K shall be deemed to be incorporated by reference in the
      prospectus included in the Registration Statement on Form F-3 (File No.
      333-141529) filed with the Securities and Exchange Commission and to be a part
      thereof from the date on which this report is filed, to the extent not
      superseded by documents or reports subsequently filed or
      furnished.</font></div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtlbio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtlbio.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!L`/X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WXG%+4%U>
M6]E`T]Q*L<2_>9N`/K60/&OAIB0-:LR1UQ*.*$F]A-I;FZ<#)_.N#\6?%/2?
M#5R;15:YN!U$>"!]:Z)/$.E:A!-%IVH6\\VPG8C@GI7RCJSSR:M=-<AA-YAW
M!A@BNC#454D^;H8UZW)'W3Z2\(?$K2O%5P]JN8+@*#MDP-WT]:[8`"OD'PT\
MZ>)=-:V4F43K@+U/-?4S^)=*L4CBU'4+>WN"@+(\@!%/$T8PG[H4*KG&\C9H
MK`_X3;PU@?\`$ZLSGI^]'-7KK7=+L;>.XNKZ&**7[C.V`U<[36YLFFKHT:*P
M3XT\-A2QUFS`'7,HH_X33PU@'^VK+#=/WHYHY7V%S1[F]16`WC;PP&"MK=D&
M/0&44[_A-/#><?VS9Y_ZZBBS6X^9=S=H/3FL/_A,O#G_`$&;/_OZ*3_A,O#G
M_09L_P#OZ*+,7-'N;@51VI>E8)\:^&@6']MV7R\G]Z.*U[2\M[ZV2XM9DFA?
M[KH<@T--;C33V)Z***0PHI'8(A9C@`9-98\0:;YA3[;!D-MV[QG.<=*:BWLB
M7)1W9JT4@(8`@Y!Y%+2*"BBB@`HJM=:A:V2AKF:.)3W=MH_6H[35K&^<I;74
M,S#J(W#8_*JY96O;0GGC>U]2[130W.#3JA.Y04444P"BBB@"M?64&H64MK<J
M&BE7:PQZU\L>.?#3>&?$=S9[!Y!<M"V.2IY_3I7U?M&,5QGQ(\*1>(_#<[1Q
M*;R!"T3=_4C-;T*BA/78RK4^>-CYR\.ZU/X>UN#4+;[R'#+G`93UKV+5OAK9
M^.EBU_3[S[))<J#(FS<N0,=.*\,FB>"9XI!AT.&'H:]?^#'BX6SRZ#=2-L8^
M9$S'(';:/2NS$0<5SPW..@TWR3-*Q\":=\.+:XU^]N_ML\,9\E"NP%NOY\5X
M_P"(=<G\1:O+J%PH5G/"CG:/2N]^+_C%-8U%=(M&)M[9LNRG`9NWUKS:QLI]
M1O(K6V0O+(V%44Z,6USU`KV3Y('6?#;PB/$_B*/[0A-G!EI"/4=*[SXXVZ6^
MAZ5$BJL:2%0!]*]$\(>&[;PWHEM:QQJ)Q&#(X');'-:6IZ+INLQI'J-G#<HA
MRJRH&`KCG63J\]M#JC1M3Y.Y\<8'H*,#T%?6G_"!^%_^@'8_]^16%XS\&^';
M/PI>W%MH]G%+&N5=8@"*Z8XJ$I)<ISO"-)NY\T8'H*,#T%.<`.P'0&O9/@]X
M>TC6=.N6U#3[:X9#P9(PQZUT59QA'F:.>$'*?*>,X'H*,#T%?6G_``@GA;MH
M5C_WY%</\4_"^AZ5X3-Q8Z7:V\H8C?'&%/2N>.*A)VY3>>%<8N5SP/:/05]3
M_##'_"O],PH`VD8'UKY9KZF^&'_)/]-^C?\`H1HQD4HIHK![LZX'-+117G'<
M5[\D:?<$=?+/\J\-D8/KLBN2`9L$Y]Z]QU`9T^X_ZYM_*O"Y"1KTA4'=YQVX
M]<UZ67Q34KGAYQ)J5.SZGO-O_J$^@J2J$VI6FGVL;7,P1=N>?I6,WQ`T!9-O
MVAL`X+;#C^5<2I3E=Q1ZTJ]*&DY)?,ZBBLJP\1Z7J0!MKI6!Z9!'\ZTPW(&1
MG&:S<6MS2,XS5XNYQGQ#L+F]L+<6Z;R'Y&?8UF?#S3;JQO[@SQ;`P&.]=[?7
MUO9(C7#`;C@<9J*QU"RNPZVS@E3\VT8Q72J\O8^SMH<,\+3EBE6YM5T-"BD4
MY&:IWFJ6>G1;[F81K[US)-Z([W)15V7:*YB7Q]H,3[1<.W'4(:L6GC+1;PJL
M=R0[=%92/YUHZ%5*[BS%8J@W;G7WF_134<2#*D$>U.K(W$&<<T$`C!&0:6@Y
MQQ0!\]?&'PC%H^K1:G8PLL%UDS8Z!_7VS7FEM<S6=PEQ;N4E0Y5AVKZP\7II
M+^'KH:OL^S!"27['MBODZ?:9Y-GW-QV_3->GA)N4;,\_%049<R&R.TLC2.2S
M,<DGN:]L^#?@N)83X@O8SYV<0`]`/7\:\=TJ6TAU6VEOHS):K(#(H[BOK/0+
MC3[G0K:;3%C6U9`55!@"EC)N,.5#PL$Y79J*5.<'-.IJ+M!XQDTZO-1WA7.>
M._\`D3=1_P"N=='7.>._^1-U'_KG5TOC7J3/X6?)[_ZQOJ:]U^!7_(+O?K_4
MUX4_^L;ZFO=?@5_R"[WZ_P!37H8O^$>?0_C?>>O5Y[\8_P#D2V_W_P"AKT*O
M/?C'_P`B6W^__0UY]/XT=M;^&SYLKZF^&'_)/]-^C?\`H1KY9KZF^&'_`"3_
M`$WZ-_Z$:[\;\"]3FP?4Z^BBBO-.XKW_`/R#[C_KFW\J\&O)&AU>65>JREA^
M!KWC4/\`D'7'_7-OY5X+J'SZI.#_`,]"/UKU<L^T?/9]M`W1'J/B^_0C=A%"
M@Y.T#_'GVK;_`.%:2&'B8"3'7=QFNL\*:='8Z)`@CPQ&2<8)K='NN*PJ8R<7
MRT]$CJHY92J0YZRNV>%:EIM_X;U!4=RK_>1EZ$9KTOP;XE?6+<P7!4S1CJ.X
MJSXOTNWOM)D,D:[P/E?'(->;^#;J2V\3VZ(V(V8JR]L5TMK%4&VO>1QQ4LOQ
M:@G>$CKOB:Q_LRU(/_+7''TK-^&))O+W))^5>IK1^)N#I-GC_GI_2L[X8'%Y
M>G_96I@E]2;M_5S2JW_:L5?H=QXAU==&TUK@XR,`#'>O)+B_U+Q/J6%)+.?N
M@<+V_P`FMKXA:I]IODM5)V(,D=LUO?#O2HETH7K1@O(QPQ'IQ2I1CAZ/M6M6
M*O.>,Q?U>+M%;F=:_#>65%:ZGP3U*GIQ[UDZ]X*O-)7SK;?+$!SCDUZ^P/X4
MR6)9H7B<9#`UA',*REKL=E3*,/*-DK,\K\*>,KJTO(;*[?=;L=HW#D'ZUZL6
M^0,#UKPOQ!IS:5K,T97"[RRC&.,\5ZGX9U$:AH$!W[V488DUKCJ4>558=3#*
ML144I8>J]5L='D<^U!8!=W:D`7@9KAOB;XOM_#_AZ>U60_;;F,I$`.F>#].*
M\Z$7)V1[4FHJ[/.OC'XO&I:DFCV4H:VA7,Q'=\]/PQ7EUO;RW4Z00H7D<X51
MW-,=VD<N[%F8Y)/>O9O@UX.\R-O$%W&"IRD"MW]\?6O5NL/3/.5Z]3R/&65D
M<JP(8'!!KUWX.>,A9W+Z'>S?NY6W0ECT..153XQ^$1I=_'K5L@6"Y;9(%_A?
MMQ[_`-*\OAFD@E66)V1U(((.*;M7IZ"3="9]I`Y`-%<A\/O%UOXHT&']Y_I<
M*!9E/7('6NOKR6G%V9Z2::N@KG/'G'@S4?\`KG_6NCKF_'O'@O4?]P?SJJ;M
M-,4_A9\H/_K&^IKW7X%?\@N]^O\`4UX4_P#K&^IKW7X%?\@N]^O]37H8O^$>
M?0_C?>>O5YY\8_\`D2V_W_Z5Z$#D5Y]\8L?\(6W^^?Y&O/I:S1VUOX;/FROJ
M;X8?\D_TWZ-_Z$:^6:^FOAOJMC:^`]-2:YC1L-P6'K7?C$W!6.;!O5G=T5FC
M7M+)_P"/V+\6%+_;VE_\_L/_`'T*\T[BS?\`_(/N/^N;?RKP>YC,NM21KU:8
M@?G7L]]K>FR64RK>Q9*$`;NO%>*WQ']J2MD8,A(/MFO5RW[1\_GO_+OU/>K!
M!'8P`$'"#D=.E6>HK-T*Z6[T>WE3&"H_*KQ!,@QP!7F35I.Y[M-IP316U-0=
M/F#<_(W\J\5T`E?$$)!((8\BO6?%=_#8:/(TCE2>FWK7F7@ZUDN/%=OM7Y59
MF)]J]/!+EH3;/#S/W\52C'>YUGQ+(;1[(C^__2L[X9?\?=[_`+JUI?$U0NDV
M:CH)/Z5G?#`9O+T?[*TX?[B_ZZBJ_P#(UCZ'.>+&E;7KCS%QAR$_W:]2\%*B
M^%;0)T^;\\G->?>/K"2WU@3;3Y3+U/KFNP^'VH1R^'DMC)F2-F&#UZY_K1B?
M>PL6N@L!^[Q]2,MV=<65LKFE^ZOK@4@&2,]J21]HW9X&<UY*U/H7H>2_$0?\
M3_/JBUTOP_P-%.1QQ_,UQ'BO4%U+7)2A)"G9D^Q/^->C^#K(V/AV'S$`9R2>
M.1[5ZN)]S#1B]V?.X*U7'3J1V1N:C?0Z99R75PP6*(;F)-?+7C7Q))XG\1W%
MYD^0&VPJ3T45]0:UH=EKUD;2^1GA;[RARN?RKE5^#_@U<`:8X4<#%P_'ZUQ8
M>I"F[R1[E:G*HK)G@/A?PY<>)M8BLH.%)!=O05]5Z1ID>DZ3!8PC"1+BL[P_
MX+T+PP\C:59^4TARS%BQ_,UO8;=RWO2KUO:OR"C25->9C>*?#L'B70I]/F`!
M<?(_]UNQKY8U[19]`U>?3[C):,_*^,;AZU]A5S6N^`O#WB2[6ZU*R\R51C<K
ME/Y56'Q'LM'L*O1]HM#YY\`^*CX3\1QW;AFMI!Y<J*>H/0U]2VMREW;QSQ'*
M.,@BN*/PA\'`\:;)[?Z0_P#C75Z5I-MHMDMM;>8(QT#N6Q^=3B*L:DN9(=&G
M*"LV7P<US?CX@>"]1)Z;!_,5TF>,U4U/3[;5["6QNX]\$HPZYQFL4[-,UDKI
MH^.'_P!8WU->Z_`O/]EWN/4?S-='_P`*@\&C_F&R'_MX?_&NA\/^%M*\,Q/'
MID!A5^HWEL_G777Q$:D.5(Y:>'<9\S9M8KSOXR`GP8=IP=_]*]$K+UWP_IWB
M.R%IJ4/G0AMP7<1S^%<L)<LD^QT5(N46CX^J47,Z@`3R`#@`.>*^EC\(O!K,
M2=.?/M,X_K1_PJ#P9_T#9/\`P(?_`!KT/KE-[HX_JDNY\T_:KC_GXE_[[-+]
MJN/^?B7_`+[-?2O_``J#P9_T#9/_``(?_&@_"'P6.NG2?^!#_P"-+ZW2_E#Z
MI+N?-:7,YD7=<S*I/)WDX%>@Z;;F]$45NVXE>"_&<=?6O4Q\(O!JG*Z:^X>L
M[G^9K2M?`VBV4Z2PP,K)]WYS6E/'4H)V1Q8S+*E?E2>QQ^@^*)O"X>PNXC(J
MMGA@",XKHF^).G+"9/LMQNQG!QC\\UMZGX7TS5`7FMT\TKMWD<USP^'%LK\W
M!9.RD<5E[3#5/>FM32-+'4%R4VFNAR/B7Q)/XBN%6)3'".B@YS[GT^E=QX&\
M/OIMJ;NX/[Z7MC&!6CIG@[2=/4$6RM(#G<>>:W@`@P,8'05%?%1=-4Z:LC3"
M8"<:KKUW>3.%^)__`""[7_KI_2LWX8?\?EY_NK_.N[UC1K/6X4BNXRX4Y&&(
MQ46C>'-/T9W:SB9&888EB<TXXJ"PWLNH3P-26-6(OHBKXOT7^U]*9$P)%^93
MC->66%[>>&=7.]"'C/SQ[L9KW7`.1UK(U3PSI>JEGN+93(0`7'!X]Z6&Q2IQ
MY*BO$,=E[K356D[21ST'Q,TYQMDMK@/CL`1_.LC7?B`;NW:&RB:,MD%F(S^0
MK4F^'%L\H:"8PJ#RNW.1^-7;/P#I<$V^:,28Z#)K53P<'S)&,H9C4CR-I>9Q
M'AKPO=:M>K*X"1`AR2,Y&>E>PK`J0K&H`"TVUM(+2,1P1+&@X`%3\Y]JY<1B
M77E=['=@L%'"PLMWN%%%%<YV!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`&!Z4444`%%%%`!1@>E%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
..%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
